If you carry an Aetna insurance card, the question is not simply "does Aetna cover GLP-1s?" The real question is which GLP-1, under which plan, for which indication, and how much paperwork are you willing to tolerate? Coverage varies significantly depending on whether you have an employer-sponsored plan, an individual marketplace plan, or Aetna Medicare Advantage. This guide breaks down exactly what to expect in 2026.
Quick Answer
Most Aetna employer-sponsored plans cover at least one GLP-1 medication for type 2 diabetes (usually Ozempic). Coverage for weight-loss indications (Wegovy, Zepbound) is less universal and depends heavily on your specific plan. Foundayo (orforglipron) was added to many Aetna formularies in early 2026 and is gaining preferred status on some plans. Prior authorization is required for virtually all GLP-1 prescriptions regardless of indication.
Aetna GLP-1 Coverage by Plan Type
| Plan Type | Ozempic (T2D) | Wegovy (Weight Loss) | Zepbound (Weight Loss) | Foundayo | Prior Auth Required |
|---|---|---|---|---|---|
| Employer-Sponsored (Large Group) | Usually covered, Tier 2–3 | Covered on ~60% of plans | Covered on ~55% of plans | Covered on ~45% of plans | Yes |
| Employer-Sponsored (Small Group) | Usually covered, Tier 3 | Covered on ~40% of plans | Covered on ~35% of plans | Varies widely | Yes |
| Individual Marketplace (ACA) | Covered with PA | Rarely covered | Rarely covered | Limited coverage | Yes |
| Aetna Medicare Advantage | Covered under Part D | Expanding in 2026 | Expanding in 2026 | Select plans | Yes |
The single biggest factor is whether your employer chose to include anti-obesity medications (AOMs) in the benefit design. Aetna offers employers the option to include weight-management drug coverage, but not all employers opt in because of cost concerns.
Ozempic Coverage on Aetna
Ozempic (semaglutide) is the most broadly covered GLP-1 across Aetna plans because it carries an FDA-approved indication for type 2 diabetes. If you have a documented T2D diagnosis, most Aetna plans will cover Ozempic after prior authorization.
Typical Criteria for Ozempic Approval
- Confirmed diagnosis of type 2 diabetes
- A1C of 7.0% or higher (some plans accept 6.5%+)
- Trial of metformin for at least 90 days (unless contraindicated or intolerant)
- Documentation from prescribing physician
If you meet these criteria, approval is straightforward in most cases. Expect copays in the $25–$75 range on preferred-tier plans, or $75–$150 on non-preferred tiers. Without any coverage, Ozempic runs approximately $935–$1,050 per month at retail pharmacy pricing.
Wegovy Coverage on Aetna
Wegovy (semaglutide for chronic weight management) has more restrictive coverage. Aetna does not automatically cover Wegovy on all plans because it requires the employer to include AOM coverage.
Typical Prior Authorization Criteria for Wegovy
- BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
- Documentation of at least 6 months of structured lifestyle modifications (diet, exercise, behavioral counseling)
- Prescription from a physician (not mid-level provider on some plans)
- No concurrent use of another GLP-1 receptor agonist
If your plan covers Wegovy, expect copays of $50–$100 on preferred tiers. If your plan does not cover AOMs, you are looking at $1,300+ per month out of pocket.
Zepbound Coverage on Aetna
Zepbound (tirzepatide for weight loss) coverage mirrors Wegovy in terms of plan design — it requires the employer to have opted into AOM coverage. However, some Aetna plans that cover Wegovy do not cover Zepbound and vice versa, because formulary negotiations differ between Novo Nordisk and Eli Lilly.
Check your specific formulary on aetna.com or call the number on your member ID card. Do not assume that coverage for one weight-loss GLP-1 means coverage for all of them.
Foundayo (Orforglipron) Coverage on Aetna
Foundayo is the newest entrant and coverage is still evolving. As an oral GLP-1 with a lower list price than injectable alternatives, Aetna has shown interest in adding it to formularies as a cost-effective option. As of early 2026:
- Some large employer plans have added Foundayo to Tier 2 (preferred brand)
- Several Aetna Medicare Advantage plans are piloting Foundayo coverage
- Individual marketplace plans have been slower to add it
The oral formulation and lower price point work in Foundayo's favor for formulary inclusion. If your plan does not yet cover it, it may be worth asking your HR department or benefits administrator to inquire about adding it at the next renewal.
Step Therapy Requirements
Aetna frequently employs step therapy for GLP-1 medications, meaning you may need to try (and fail) cheaper options before the plan approves a more expensive one.
Common Step Therapy Sequence
- For T2D: Metformin → sulfonylurea or SGLT2 inhibitor → GLP-1 agonist
- For weight loss: Documented lifestyle modifications → sometimes phentermine or naltrexone/bupropion → GLP-1 agonist
Step therapy can delay access by 3–6 months. If you have clinical reasons to skip a step (e.g., metformin intolerance, contraindications to phentermine), your physician can request a step therapy exception with supporting documentation.
The Prior Authorization Process
Aetna's prior authorization process for GLP-1s typically works as follows:
- Your physician submits a PA request — usually via CoverMyMeds or Aetna's provider portal
- Aetna reviews within 5–15 business days (urgent requests may be expedited to 72 hours)
- Approval or denial letter is sent to you and your physician
- If approved, the authorization is typically valid for 6–12 months and must be renewed
To speed up the process, make sure your physician includes all required clinical documentation upfront: current BMI, comorbidity list, A1C (if applicable), and a summary of prior weight-management attempts.
What to Do If Aetna Denies Your GLP-1
Denials are common, especially for weight-loss indications. Do not give up — the appeals process exists for a reason and success rates are meaningful.
Internal Appeal (First Level)
- You have 180 days from the denial to file an internal appeal
- Include a letter of medical necessity from your physician
- Attach supporting clinical evidence (lab results, weight history, comorbidity documentation)
- Reference clinical guidelines from the Obesity Medicine Association or Endocrine Society
External Review (Second Level)
- If the internal appeal is denied, you can request an independent external review
- An independent third-party reviewer examines your case
- External review decisions are binding on Aetna
- Many patients who lose internal appeals win on external review
Peer-to-Peer Review
Your physician can request a peer-to-peer review where they speak directly with an Aetna medical director. This is often the most effective path because it allows your doctor to make the clinical case in real time rather than through paperwork.
Cost With vs. Without Aetna Coverage
| Medication | With Aetna Coverage (Preferred Tier) | With Aetna Coverage (Non-Preferred) | Without Coverage (Cash) |
|---|---|---|---|
| Ozempic | $25–$75/month | $75–$150/month | $935–$1,050/month |
| Wegovy | $50–$100/month | $100–$250/month | $1,300–$1,350/month |
| Zepbound | $50–$100/month | $100–$250/month | $1,060–$1,100/month |
| Foundayo | $25–$60/month | $60–$125/month | $149–$299/month |
Note that Foundayo's cash price is dramatically lower than the injectable alternatives, making it the most accessible option even without insurance coverage.
Tips for Maximizing Your Aetna GLP-1 Coverage
- Check your formulary first: Log into aetna.com and search for the specific medication before your doctor's appointment
- Ask about Foundayo: If injectable GLP-1s are not covered, the oral option may be on a different tier
- Use manufacturer savings cards: Novo Nordisk and Eli Lilly offer copay assistance programs that can reduce costs even with insurance
- Document everything: Keep records of all diet, exercise, and previous medication trials
- Request expedited review: If your condition is urgent, your physician can request an expedited PA decision
- Talk to HR: If your employer plan does not cover AOMs, advocate for adding coverage at the next benefits renewal
Manufacturer Savings Programs
Even with Aetna coverage, copays can be significant. Consider stacking manufacturer savings:
- Ozempic Savings Card: Eligible patients may pay as little as $25 for up to 24 months
- Wegovy Savings Offer: Reduces copays for commercially insured patients
- Zepbound Savings Card: Eligible patients may pay as little as $25/month
- Foundayo Patient Access: Launch pricing programs available — check manufacturer website
These programs are generally available to commercially insured patients and are not valid for government insurance (Medicare, Medicaid, Tricare).
Bottom Line
Aetna GLP-1 coverage in 2026 is better than it was two years ago, but it is far from universal. Diabetes indications are broadly covered. Weight-loss indications depend on your employer's benefit design. Prior authorization is unavoidable. The good news: Foundayo's arrival as a lower-cost oral option is creating new coverage pathways, and the appeals process works for patients willing to push through it.
Use MedSwitcher's comparison tools to see which GLP-1 fits your coverage situation, compare cash-pay alternatives, and find the most cost-effective path to treatment.
Sources
- Aetna Clinical Policy Bulletin: Anti-Obesity Medications, updated January 2026.
- Aetna Pharmacy Clinical Policy: GLP-1 Receptor Agonists, 2026.
- CVS Caremark / Aetna Formulary Listings, Q1 2026.
- Obesity Medicine Association clinical guidelines.
- MedSwitcher insurance coverage database, updated April 2026.